Iovance Biotherapeutics, Inc. IOVA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

50/100

3/7 Pass

SharesGrow Intrinsic Value

Il y a eu 50 transactions d'initiés récentes enregistrées pour Iovance Biotherapeutics, Inc. (IOVA), dont 20 achats et 28 ventes. Le total des achats d'initiés s'élève à $107.19K et le total des ventes d'initiés à $50.63K.

Les initiés notables ayant une activité récente comprennent Bilinsky Igor, Vogt Frederick G, Graf Finckenstein Friedrich. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — IOVA

Date	Nom	Rôle	Type de Transaction	Actions	Prix Moyen	Valeur	Actions détenues
2026-03-09	Bilinsky Igor	Chief Operating Officer	Attribution de RSU	117,500	-	-	117,500
2026-03-09	Vogt Frederick G	Interim CEO & General Counsel	Attribution de RSU	235,000	-	-	235,000
2026-03-09	Graf Finckenstein Friedrich	Chief Medical Officer	Attribution de RSU	58,750	-	-	58,750
2026-03-09	Roche Corleen M.	Chief Financial Officer	Attribution de RSU	132,200	-	-	132,200
2026-03-09	Puri Raj K.	Chief Regulatory Officer	Attribution de RSU	117,500	-	-	117,500
2026-03-09	Kirby Daniel Gordon	Chief Commercial Officer	Attribution de RSU	132,200	-	-	132,200
2026-03-05	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	31,246	-	-	62,504
2026-03-05	Vogt Frederick G	Interim CEO & General Counsel	Exercice d'Options (Vente)	62,493	-	-	125,007
2026-03-05	Graf Finckenstein Friedrich	Chief Medical Officer	Exercice d'Options (Vente)	31,246	-	-	62,504
2026-03-05	Puri Raj K.	Chief Regulatory Officer	Exercice d'Options (Vente)	39,059	-	-	78,131
2026-03-02	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	3,517	-	-	-
2026-03-02	Vogt Frederick G	Interim CEO & General Counsel	Exercice d'Options (Vente)	10,418	-	-	-
2026-03-02	Graf Finckenstein Friedrich	Chief Medical Officer	Exercice d'Options (Vente)	3,907	-	-	-
2026-03-02	Puri Raj K.	Chief Regulatory Officer	Exercice d'Options (Vente)	5,470	-	-	21,878
2026-02-24	Kirby Daniel Gordon	Chief Commercial Officer	Exercice d'Options (Vente)	150,000	-	-	-
2026-02-10	Kirby Daniel Gordon	Chief Commercial Officer	Retenue Fiscale RSU	16,450	$2.60	$42.77K	53,546
2025-12-02	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	3,516	-	-	3,517
2025-12-02	Vogt Frederick G	Interim CEO & General Counsel	Exercice d'Options (Vente)	10,417	-	-	10,418
2025-12-02	Graf Finckenstein Friedrich	Chief Medical Officer	Exercice d'Options (Vente)	3,906	-	-	3,907
2025-12-01	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	8,789	-	-	43,949
2025-12-01	Vogt Frederick G	Interim CEO & General Counsel	Exercice d'Options (Vente)	41,669	-	-	208,344
2025-12-01	Graf Finckenstein Friedrich	Chief Medical Officer	Exercice d'Options (Vente)	8,789	-	-	43,949
2025-12-01	Puri Raj K.	Chief Regulatory Officer	Exercice d'Options (Vente)	5,469	-	-	27,348
2025-09-02	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	3,516	-	-	7,033
2025-09-02	Vogt Frederick G	Interim CEO & General Counsel	Exercice d'Options (Vente)	10,417	-	-	20,385
2025-09-02	Graf Finckenstein Friedrich	Chief Medical Officer	Exercice d'Options (Vente)	3,907	-	-	7,813
2025-09-02	Puri Raj K.	Chief Regulatory Officer	Exercice d'Options (Vente)	5,470	-	-	32,817
2025-08-06	Roche Corleen M.	Officer	Inconnu	-	-	-	-
2025-08-06	Roche Corleen M.	Chief Financial Officer	Attribution de RSU	150,000	-	-	150,000
2025-06-30	Rosinack Matthew W.	SVP, Finance (int. Pfo & Pao)	Inconnu	75,000	$25.30	$1.9M	-
2025-06-13	Yarno Wendy L	Director	Attribution de RSU	67,546	-	-	67,546
2025-06-13	Weiser Michael	Director	Attribution de RSU	67,546	-	-	67,546
2025-06-13	Maynard Ryan D	Director	Attribution de RSU	67,546	-	-	67,546
2025-06-13	Countouriotis Athena	Director	Attribution de RSU	67,546	-	-	67,546
2025-06-13	Dukes Iain D.	Director	Attribution de RSU	135,092	-	-	135,092
2025-06-05	Kirby Daniel Gordon	Chief Commercial Officer	Achat Informatif	30,000	$1.84	$55.2K	30,000
2025-06-02	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	3,516	-	-	10,549
2025-06-02	Vogt Frederick G	Interim CEO & General Counsel	Exercice d'Options (Vente)	10,417	-	-	31,252
2025-06-02	Bellemin Jean-marc	Chief Financial Officer	Retenue Fiscale RSU	4,464	$1.76	$7.86K	60,529
2025-06-02	Graf Finckenstein Friedrich	Chief Medical Officer	Exercice d'Options (Vente)	3,906	-	-	11,720
2025-06-02	Puri Raj K.	Chief Regulatory Officer	Exercice d'Options (Vente)	5,469	-	-	38,287
2025-05-23	Puri Raj K.	Chief Regulatory Officer	Achat Informatif	5,600	$1.74	$9.74K	206,852
2025-05-14	Vogt Frederick G	Interim CEO & General Counsel	Achat Informatif	25,000	$1.69	$42.25K	374,646
2025-03-14	Puri Raj K.	Chief Regulatory Officer	Exercice d'Options (Vente)	8,334	-	-	-
2025-03-05	Bilinsky Igor	Chief Operating Officer	Attribution de RSU	93,750	-	-	93,750
2025-03-05	Vogt Frederick G	Interim CEO & General Counsel	Attribution de RSU	187,500	-	-	187,500
2025-03-05	Bellemin Jean-marc	Chief Financial Officer	Attribution de RSU	93,750	-	-	93,750
2025-03-05	Graf Finckenstein Friedrich	Chief Medical Officer	Attribution de RSU	93,750	-	-	93,750
2025-03-05	Puri Raj K.	Chief Regulatory Officer	Attribution de RSU	117,190	-	-	117,190
2025-03-03	Bilinsky Igor	Chief Operating Officer	Exercice d'Options (Vente)	3,516	-	-	14,065

■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration